Biogen Shares Surge 9% on Positive Alzheimer’s Drug Trial Data
Biogen’s mid-stage trial results for Alzheimer’s therapy diranersen boosted premarket shares by nearly 9% Thursday. Biogen (BIIB) climbed approximately 9% in premarket trading after releasing topline data from a Phase 2 trial of diranersen, an experimental Alzheimer’s trea